Last reviewed · How we verify

Lidocaine HCl 1%

HaEmek Medical Center, Israel · FDA-approved active Small molecule

Lidocaine HCl blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia.

Lidocaine HCl blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia. Used for Local anesthesia for infiltration, nerve blocks, and topical application, Pain relief in minor surgical and dental procedures.

At a glance

Generic nameLidocaine HCl 1%
Also known asESRACAIN, Lidocaine, Dynexan Mundgel®, Xylocaine, Lidocaine Viscous
SponsorHaEmek Medical Center, Israel
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Lidocaine is a local anesthetic that works by reversibly inhibiting sodium influx through voltage-gated sodium channels in the neuronal cell membrane. This prevents depolarization and the generation of action potentials, thereby blocking pain signal transmission. At 1% concentration, it is suitable for infiltration anesthesia, topical application, and regional anesthesia procedures.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: